TNFRSF8 and Hodgkins lymphoma: The murine anti-CD30 monoclonal antibody (HRS3), and HRS3-based bispecific antibody (AFM13) and recombinant fusion protein combined with cytokines, and CAR-T have been developed and applied to the specific immunotherapy of Hodgkin’s lymphoma, including CAR-T therapy (Hombach et al., 1993; Renner et al., 2000; Jahn et al., 2012; Grover and Savoldo, 2019).